Chicago, GenomeWeb — A new study by researchers from Memorial Sloan Kettering Cancer Center has demonstrated the
predictive power of an AR - V7 protein expression test using Epic Sciences» non-EPCAM-based
circulating tumor
cell detection platform, which could help guide treatment decisions for men with metastatic castration - resistant prostate cancer.